Apnimed

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Apnimed sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 12 completed early-phase tilt top decile by trial count

Apnimed: 12 sponsored US clinical trials, none currently recruiting.

Apnimed sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 2 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is OSA, with 1 trials.

Top-decile sponsor footprint

Apnimed ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 2

Study That Tests AD109 in Patients Taking GLP-1 Drugs

NCT06400615
COMPLETED Phase 3

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

NCT05813275
COMPLETED Phase 3

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

NCT05811247
COMPLETED Phase 2

AD816 Crossover Study

NCT05793684
COMPLETED Phase 2

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

NCT05071612
COMPLETED Phase 1

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

NCT05101122
COMPLETED Phase 2

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

NCT04905979
COMPLETED Phase 2

AD109 Dose Finding in Mild to Moderate OSA

NCT04631107
COMPLETED Phase 2

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

NCT04645524
COMPLETED Phase 2

Crossover Trial of AD109 in Obstructive Sleep Apnea

NCT04580394
COMPLETED Phase 2

Crossover Trial of AD036 in Obstructive Sleep Apnea

NCT04445688
COMPLETED Phase 2

Trial of AD036 in Obstructive Sleep Apnea

NCT03845023

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 9
Phase 3 2

Therapeutic Areas

OSA 1
Obstructive Sleep Apnea 1

How the Apnimed early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 12 completed (100%).

Phase mix: 2 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: OSA (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Apnimed: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Apnimed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share ApnimedAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Apnimed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Apnimed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Apnimed page

12 registered trials is a research-attention snapshot, not an endorsement of Apnimed or any single study.

  • None of Apnimed's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • OSA is the condition Apnimed studies most, compare against other sponsors active in the same condition before evaluating a specific study. See OSA trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Apnimed pipeline card: 12 registered trials from official public datasets.Report a data error.